Movatterモバイル変換


[0]ホーム

URL:


CN109734775A - A kind of refining methd of enalapril maleate - Google Patents

A kind of refining methd of enalapril maleate
Download PDF

Info

Publication number
CN109734775A
CN109734775ACN201811650284.3ACN201811650284ACN109734775ACN 109734775 ACN109734775 ACN 109734775ACN 201811650284 ACN201811650284 ACN 201811650284ACN 109734775 ACN109734775 ACN 109734775A
Authority
CN
China
Prior art keywords
enalapril maleate
refining methd
water
enalapril
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811650284.3A
Other languages
Chinese (zh)
Inventor
孙守飞
刘佩佩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CISEN PHARMACEUTICAL Co Ltd
Original Assignee
CISEN PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CISEN PHARMACEUTICAL Co LtdfiledCriticalCISEN PHARMACEUTICAL Co Ltd
Priority to CN201811650284.3ApriorityCriticalpatent/CN109734775A/en
Publication of CN109734775ApublicationCriticalpatent/CN109734775A/en
Pendinglegal-statusCriticalCurrent

Links

Landscapes

Abstract

The invention belongs to field of medicine preparing technology, are related to a kind of refining methd of enalapril maleate.The refining methd comprises the following processes: enalapril maleate crude product is added in water-organic solvent mixed solvent system, it is heated to 30-80 DEG C and stirs dissolution, after stirring 30 minutes, it is cooled to 0-20 DEG C of crystallization, filtering, with 0-10 DEG C of mixed solvent filter wash cake is cooled to twice, 20-60 DEG C of vacuum drying obtains enalapril maleate of the purity 99.5% or more.Compared with prior art, the refining methd of enalapril maleate of the present invention refines enalapril maleate with the method that temperature control combines using the difference of enalapril maleate dissolution properties in all kinds of solvents, the quality of products obtained therefrom is stablized, yield and purity further improve, yield is 84% or more, and quality is higher than standards of pharmacopoeia, detects through HPLC, purity is greater than 99.5%, and total impurities content is lower than 0.04.

Description

A kind of refining methd of enalapril maleate
Technical field
The invention belongs to field of medicine preparing technology, it particularly relates to arrive a kind of purification side of enalapril maleateMethod.
Background technique
Enalapril maleate (Enalapril Maleate) also known as Cinvoril, CAS registration number: 76095-16-4 changesScientific name: N- [(s)-ethoxycarbonyl-3-phenylpropyl]-L-Ala-L-Pro maleate, chemical structural formula are as follows:
Enalapril maleate is one of the main component of Oral glucose tolerance test Enalapril, and Enalapril is by Mo Shadong systemMedicine company (Merck&Co Inc) develops, and is approved for treating each phase essential hypertension, renovascular hypertension, eachGrade heart failure, prevention symptomatic heart failure and prevention left ventricular insufficiency patient coronary ischemia event.
Enalapril maleate can reduce the blood pressure of hypertensive patient, and can improve the symptom and body of chronic heart failureSign.Enalapril maleate is angiotensin converting enzyme inhibitor, is hydrolyzed into enalaprilat in vivo after oral(Enalaprilat).The latter inhibits Angiotensin-Converting, reduces angiotensinⅡ content, causes systemic vasodilatation,And generate the effect to reduce blood pressure.
The report of synthetic method about enalapril maleate, including patent document US4374829, periodical literatureDrugs Fut 1982,7 (8), 556 and Nature 1980,288,280-283, wherein being not directed to enalapril maleatePurifying, refining methd.
Chinese patent CN1274362A discloses a kind of refining methd for preparing high-purity enalapril maleate, this methodEnalapril maleate crude product is dissolved in alkaline solution, adjust pH to 6.0 ± 0.5, then with acid neutralize adjusting PH to 2.3 ±0.5, cooling precipitates crystal, filtration washing, and enalapril maleate finished product is obtained after vacuum drying.
It can be seen that the purifying of enalapril maleate, refining methd are all made of the place of " alkali-soluble acid analysis " in the prior artReason method, however, should need to carry out sternly the addition speed of acid and the pH value of solution in " alkali-soluble acid analysis " method operating processThe control of lattice, so that operating procedure and production cost are increased, in addition, enalapril is in an acidic solution compared with facile hydrolysis, degradationFor enalaprilat, i.e. N- [(S) -1- carboxyl -3- phenylpropyl]-L-Ala-L-Pro;2,4 dichloro benzene base -2- (- 1H-Imidazoles) ethyl alcohol.Use the method for " alkali-soluble acid analysis " when refining to enalapril maleate, to enalapril maleateIn alkaline solution when acid adding, it may appear that the acid too strong situation in the part of solution in the short time causes enalapril difficult to understand to hydrolyze, rawAt enalaprilat.Therefore, traditional " alkali-soluble acid analysis " refining methd can not steadily, fully remove the impurity.
Summary of the invention
In order to solve the above technical problems, the present invention provides a kind of simple process, at low cost, safe and reliable, stability is good,Convenient for the Aceglutamide and sodium chloride injection and preparation method thereof of clinical use.
A kind of refining methd of enalapril maleate of the present invention, the refining methd comprise the following processes: willEnalapril maleate crude product is added in water-organic solvent mixed solvent system, is heated to 30-80 DEG C and is stirred dissolution, stirring 30After minute, it is cooled to 0-20 DEG C of crystallization, is filtered, with 0-10 DEG C of mixed solvent filter wash cake is cooled to twice, 20-60 DEG C of vacuum is dryThe dry enalapril maleate for obtaining purity 99.5% or more.
A kind of refining methd of enalapril maleate of the present invention, the organic solvent are selected from methanol, ethyl alcohol, thirdKetone, second eyeball, normal propyl alcohol, isopropanol, n-butanol, isobutanol, ethylene glycol, methylene chloride, dimethyl sulfoxide, tetrahydrofuran, N, N- bis-One or more of methylformamide or DMAC N,N' dimethyl acetamide.
A kind of refining methd of enalapril maleate of the present invention, the weight of the enalapril maleate and waterThan for 1:10-40, the volume ratio of polar organic solvent and water is 0.1-50:1.
A kind of refining methd of enalapril maleate of the present invention, the weight of the enalapril maleate and waterThan for 1:10-40, the volume ratio of polar organic solvent and water is 0.1-50:1.
The temperature of a kind of refining methd of enalapril maleate of the present invention, the heating stirring dissolution is 20-90 DEG C, the temperature of cooling crystallization is 0-20 DEG C.
A kind of refining methd of enalapril maleate of the present invention, the enalapril maleate and washing filter cakeWeight ratio in the mixed solvent water is 1:10-40, and the volume ratio of polar organic solvent and water is 0.1-50:1, cleaning solution temperatureDegree is 0-20 DEG C.
A kind of refining methd of enalapril maleate of the present invention, the vacuum drying temperature are 20-60 DEG C.
Research is found: at different temperatures, dissolution properties has enalapril maleate in solvent of different natureLarger difference, thus the temperature of one precipitation process of dissolution by adjusting enalapril maleate and the variation of solvent property, are obtainedThe product for obtaining high-purity and yield avoids it is not necessary that acid is added in subtractive process and uses " alkali-soluble acid analysis " in the prior artMethod leads to the problem of product hydrolysis, has the advantages that easy to operate, production cost is low, product purity is high, is suitable for industrializingIt produces and uses.
Compared with prior art, the refining methd of enalapril maleate of the present invention utilizes enalapril maleateThe difference of dissolution properties refines enalapril maleate with the method that temperature control combines in all kinds of solvents, products obtained therefromQuality is stablized, and yield and purity further improve, and yield is 84% or more, and quality is higher than standards of pharmacopoeia, examines through HPLCIt surveys, purity is greater than 99.5%, and total impurities content is lower than 0.04.
Detailed description of the invention
1 products obtained therefrom content detection result of Fig. 1 embodiment.2 products obtained therefrom content detection result of Fig. 2 embodiment.Fig. 3 is implemented3 products obtained therefrom content detection result of example.4 products obtained therefrom content detection result of Fig. 4 embodiment.
Specific embodiment
The refining methd of enalapril maleate of the present invention is described further combined with specific embodiments below,But the scope of protection of the present invention is not limited thereto.
Embodiment 1
20.0g enalapril maleate crude product is added in 320ml purified water, is heated to 60 DEG C, is stirred 2 hours, it is coldBut to 5 DEG C, crystallization 2 hours are stood, filtering, filter cake is washed twice with 5 DEG C of purified water, is dried in vacuo 4 hours, obtains at 50 DEG CEnalapril maleate 18.0g, yield 90.0%.It is detected through HPLC, wherein appearance time 13.7 minutes are enalapril, peakArea is 99.52%.
Embodiment 2
20.0g enalapril maleate crude product is added in 100ml acetonitrile-water (9:1), is heated to 80 DEG C, stirring is extremelySolid continues stirring 30 minutes after being completely dissolved, be cooled to 10 DEG C, stands crystallization 4 hours, filtering, 10 DEG C of acetonitrile-of filter cakeWater (9:1) washes twice, and is dried in vacuo 4 hours at 30 DEG C, obtains enalapril maleate 18.2g, yield 91.0%.Through HPLCDetection wherein appearance time 15.6 minutes is, enalapril, peak area 99.75%.
Embodiment 3
20.0g enalapril maleate crude product is added to 100ml methylene chloride-methanol-water of the river of blueness containing 0.5g rattan alkane AIn (5:3:2), 80 DEG C are heated to, stirring continues stirring 30 minutes after being completely dissolved to solid, be cooled to 3 DEG C, and it is small to stand crystallization 4When, filtering, filter cake is washed twice with 3 DEG C of methylene chloride-methanol-water (5:3:2), is dried in vacuo 4 hours at 40 DEG C, obtains horseCome sour enalapril 19.4g, yield 97.1%.It is detected through HPLC, wherein appearance time 13.7 minutes are enalapril, peak faceProduct is 99.68%.
Embodiment 4
20.0g enalapril maleate crude product is added to 100ml methylene chloride-methanol-water of the river of blueness containing 0.5g rattan alkane BIn (5:3:2), 80 DEG C are heated to, stirring continues stirring 30 minutes after being completely dissolved to solid, be cooled to 3 DEG C, and it is small to stand crystallization 4When, filtering, filter cake is washed twice with 3 DEG C of methylene chloride-methanol-water (5:3:2), is dried in vacuo 4 hours at 40 DEG C, obtains horseCome sour enalapril 16.8g, yield 84.0%.It is detected through HPLC, wherein appearance time 13.7 minutes are enalapril, peak faceProduct is 99.68%.
Using the purity of HPLC method measurement enalapril maleate in the present invention, chromatographic condition is as follows: chromatographic column:RLRP-S100A 5μm 250*4.6μm;Mobile phase: mixture of acetonitrile-phosphate buffer (4:6);Column temperature: 70 DEG C;Detection wavelength:215nm;Sampling volume: 10 μ L;Flow velocity: 1.0ml/min.

Claims (10)

CN201811650284.3A2018-12-312018-12-31A kind of refining methd of enalapril maleatePendingCN109734775A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN201811650284.3ACN109734775A (en)2018-12-312018-12-31A kind of refining methd of enalapril maleate

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN201811650284.3ACN109734775A (en)2018-12-312018-12-31A kind of refining methd of enalapril maleate

Publications (1)

Publication NumberPublication Date
CN109734775Atrue CN109734775A (en)2019-05-10

Family

ID=66363007

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN201811650284.3APendingCN109734775A (en)2018-12-312018-12-31A kind of refining methd of enalapril maleate

Country Status (1)

CountryLink
CN (1)CN109734775A (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4374829A (en)*1978-12-111983-02-22Merck & Co., Inc.Aminoacid derivatives as antihypertensives
CN1234804A (en)*1997-07-221999-11-10钟渊化学工业株式会社Process for preparing pharmacologically acceptable salts of N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl amino acids
CN1274362A (en)*1998-07-212000-11-22钟渊化学工业株式会社Method for crystallizing maleic acid salt of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline
US6541635B1 (en)*2002-03-292003-04-01Everlight Usa, Inc.Method for producing angiotensin converting enzyme inhibitor
JP2005060291A (en)*2003-08-112005-03-10Nitto Denko Corp Patch containing enalapril analogue
WO2006099058A2 (en)*2005-03-092006-09-21Nitromed, Inc.Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
CN104744404A (en)*2015-02-272015-07-01张旻Stable hydrochlorothiazide crystalline compound, and composite enalapril maleate pharmaceutical composition thereof
CN108586572A (en)*2018-04-182018-09-28日照市普达医药科技有限公司A kind of preparation method of high-purity enalapril maleate and its crystal form
CN109021064A (en)*2017-06-092018-12-18扬子江药业集团有限公司A kind of preparation method of enalapril maleate

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4374829A (en)*1978-12-111983-02-22Merck & Co., Inc.Aminoacid derivatives as antihypertensives
CN1234804A (en)*1997-07-221999-11-10钟渊化学工业株式会社Process for preparing pharmacologically acceptable salts of N-(1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl amino acids
CN1274362A (en)*1998-07-212000-11-22钟渊化学工业株式会社Method for crystallizing maleic acid salt of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline
US6541635B1 (en)*2002-03-292003-04-01Everlight Usa, Inc.Method for producing angiotensin converting enzyme inhibitor
JP2005060291A (en)*2003-08-112005-03-10Nitto Denko Corp Patch containing enalapril analogue
WO2006099058A2 (en)*2005-03-092006-09-21Nitromed, Inc.Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
CN104744404A (en)*2015-02-272015-07-01张旻Stable hydrochlorothiazide crystalline compound, and composite enalapril maleate pharmaceutical composition thereof
CN109021064A (en)*2017-06-092018-12-18扬子江药业集团有限公司A kind of preparation method of enalapril maleate
CN108586572A (en)*2018-04-182018-09-28日照市普达医药科技有限公司A kind of preparation method of high-purity enalapril maleate and its crystal form

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘亚南等: "马来酸依那普利片稳定性研究", 《药学研究》*
王紫华: "马来酸依那普利片的制备工艺研究", 《当代医药论丛》*

Similar Documents

PublicationPublication DateTitle
EP2170904B1 (en)Process for preparing amorphous rifaximin and the amorphous rifaximin thus obtained
CN115505051A (en)Method for refining sugammadex sodium
CN103936727A (en)High-purity canagliflozin compound and preparation method thereof
CN104277024B (en)A kind of method extracting naringenin from shaddock
CN108558909A (en)The method of active ingredient in synthetical recovery clavulanic acid tert-butylamine salt crystalline mother solution
CN109734775A (en)A kind of refining methd of enalapril maleate
CN107163050B (en)A kind of synthetic method of valganciclovir hydrochloride
CN103435567A (en)Valsartan refining method
CN111718329A (en) A kind of delafloxacin impurity IV and product refining method
CN113636924A (en) A kind of extraction and purification method for producing coenzyme Q10 by fermentation method
CN116891513B (en)Process for preparing triamcinolone acetonide and intermediates thereof
CN101560188B (en)Method for separating and purifying 2-methylimidazole crystal impurity
CN116102532B (en) Method for recovering lipoic acid from lipoic acid crystal mother liquor
CN106749229B (en)A kind of process for purification of pervone
CN103172683B (en)A kind of preparation method of Dalacina
CN105646535A (en)Synthesis method of cefotaxime sodium
CN105440163A (en)Method for preparing and purifying enoxaparin sodium
KR101574252B1 (en)Novel Preparation for Taltirelin by Solid Phase Peptide Synthetic Method
CN107759609A (en)A kind of purification process of asenapine
CN108440324B (en)Ornithine aspartate and crystallization method thereof
CN113461769A (en)Preparation method of betulin
CN105693723B (en)A kind of preparation method of CBZ- valganciclovir monoesters
CN104650048B (en)Purification method of olmesartan medoxomil condensation compound
CN105732630B (en)A kind of preparation method of CBZ- valganciclovir
CN111718331A (en) Impurities I and II of Delafloxacin and product refining method

Legal Events

DateCodeTitleDescription
PB01Publication
PB01Publication
SE01Entry into force of request for substantive examination
SE01Entry into force of request for substantive examination
RJ01Rejection of invention patent application after publication

Application publication date:20190510

RJ01Rejection of invention patent application after publication

[8]ページ先頭

©2009-2025 Movatter.jp